Hoba Therapeutics, a Danish biotech from Novo, raises $25M to develop pain and hearing loss drugsnews2023-12-11T07:00:09+00:00December 11th, 2023|Endpoints News|
Cigna’s merger talks with Humana have reportedly fallen throughnews2023-12-10T20:59:22+00:00December 10th, 2023|Endpoints News|
Autoimmune patients in CAR-T study see striking improvements across lupus and other diseasesnews2023-12-10T18:43:52+00:00December 10th, 2023|Endpoints News|
Roche partner touts early allogeneic CAR-T data at ASH, but durability remains key questionnews2023-12-10T17:00:46+00:00December 10th, 2023|Endpoints News|
Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data at ASHnews2023-12-10T01:16:27+00:00December 10th, 2023|Endpoints News|
BeiGene builds out long-term case for Brukinsa in CLL, despite an overall survival miss: #ASH23news2023-12-09T22:45:43+00:00December 9th, 2023|Endpoints News|
AbbVie’s $8.7B neuro gambit; Landmark sickle cell approvals; Roche buys a GLP-1 company; Endpoints 100 biotech survey; and morenews2023-12-09T11:00:44+00:00December 9th, 2023|Endpoints News|
Bluebird sinks on pricing plans, lack of priority review voucher for sickle cell gene therapynews2023-12-08T20:04:25+00:00December 8th, 2023|Endpoints News|
AbbVie teams with Parkinson’s disease foundation for ‘Flipping the Switch’ effortnews2023-12-08T19:59:23+00:00December 8th, 2023|Endpoints News|
New research points to potential link between GLP-1s and lowered risk of colorectal cancernews2023-12-08T19:46:45+00:00December 8th, 2023|Endpoints News|
